Skip to main content

Advertisement

Table 1 Summary of patient demographic data, lesion type, treatment regimen and geographic atrophy progression

From: Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration

Eye Patient 1 (77, WM) Patient 2 (76, WF) Patient 3 (94, WF) Patient 4 (95, WF)
OD OS OD OS OD OS OD OS
Injections received 81 ranibizumab 18 ranibizumab; 36 aflibercept 51 ranibizumab 6 bevacizumab; 70 ranibizumab
NV Type 1 Type 1 Type 1 Type 1
Regimen schedule q6 weeks q6–7 weeks q7–8 weeks q4–5 weeks
Total follow-up interval 120 months 62 months 99 months 95 months
Initial visit (mm2) 0.38 0.05 0.00 0.00 0.00 0.00 0.56 4.62
Last visit (mm2) 1.73 9.65 0.30 6.72 0.07 5.72 0.61 7.84
ΔGA Last − Initial 1.35 9.60 0.30 6.72 0.07 5.72 0.05 3.22
Progression rate 1 of GA (mm2/month) 0.01125 0.08 0.00483 0.10838 0.00070 0.05777 0.00052 0.03389
Progression rate 2 of GA (mm2/injection) 0.01666 0.00555 0.00137 0.00065
  1. WM white male, WF white female, OD right eye, OS left eye, CNV choroidal neovascularization, mm 2 millimeter2, ΔGA change in geographic atrophy